

# 2019 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

<https://marketpublishers.com/r/2BA637052F7EN.html>

Date: April 2019

Pages: 60

Price: US\$ 1,799.00 (Single User License)

ID: 2BA637052F7EN

## Abstracts

The global clinical trial report- “2019 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Focal Segmental Glomerulosclerosis (FSGS). It presents in-depth analysis of Focal Segmental Glomerulosclerosis (FSGS) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Focal Segmental Glomerulosclerosis (FSGS).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Focal Segmental Glomerulosclerosis (FSGS) clinical trials by-

Current Trial Status

Type of the trial

Sponsor Type

Enrollment Trends

Region

Countries

Trial Phase

The report also identifies the potential drug candidates under development for treatment of Focal Segmental Glomerulosclerosis (FSGS)

The research work is prepared through extensive and continuous research on Focal Segmental Glomerulosclerosis (FSGS) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

#### Report Scope and Coverage:

All major trials from 2010 to 2019 and planned trials are included in the report scope.

Drug candidates currently being researched for administering Focal Segmental Glomerulosclerosis (FSGS) patients are identified

The report includes panorama of Focal Segmental Glomerulosclerosis (FSGS) clinical trials across the globe

Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided

Companies and universities focusing on Focal Segmental Glomerulosclerosis (FSGS) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)

Average Enrollment number, insights into enrollment trends, company wise enrollment are included

Both interventional and observational studies are analyzed

News and latest developments for the past one year are presented in the report

## Contents

### **1. TABLE OF CONTENTS**

1.1 List of Figures

1.2 List of Tables

### **2. EXECUTIVE SUMMARY**

2.1 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Overview, 2019

2.2 Premium Insights into Clinical Trials

2.2.1 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Region

2.2.2 Average Enrollment of Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials

2.2.3 Companies participating in Trials

2.2.4 Drugs under Study for Focal Segmental Glomerulosclerosis (FSGS) Treatment, 2019

### **3. REGION WISE FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) CLINICAL TRIALS**

3.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country

3.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country

3.3 North America Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country

3.4 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country

3.5 South and Central America Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Country

### **4. FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) CLINICAL TRIAL TRENDS**

4.1 Start Year wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials

4.2 Phase wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials

4.3 Trial Status wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials

4.4 Trial Type wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials

### **5. FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AVERAGE**

## **ENROLLMENT TRENDS**

- 5.1 Average Enrollment in Focal Segmental Glomerulosclerosis (FSGS) Trials by Year
- 5.2 Average Enrollment in Focal Segmental Glomerulosclerosis (FSGS) Trials by Phase
- 5.3 Average Enrollment in Focal Segmental Glomerulosclerosis (FSGS) Trials by Status
- 5.4 Average Enrollment in Focal Segmental Glomerulosclerosis (FSGS) Trials by Type of Trial

## **6. COMPANIES PARTICIPATING IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) CLINICAL TRIALS**

- 6.1 Focal Segmental Glomerulosclerosis (FSGS) Trials by Sponsor Type
- 6.2 Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Sponsor Type
- 6.3 Subjects Recruited by Leading Sponsors

## **7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS**

- 7.1 Focal Segmental Glomerulosclerosis (FSGS) Trials- Phase
- 7.2 Focal Segmental Glomerulosclerosis (FSGS) Trials- Phase
- 7.3 Focal Segmental Glomerulosclerosis (FSGS) Trials- Phase
- 7.4 Focal Segmental Glomerulosclerosis (FSGS) Trials- Phase

## **8. APPENDIX**

- 8.1 Report Guidance
- 8.2 Research Methodology
- 8.3 Abbreviations
- 8.4 Definitions
- 8.5 Sources
- 8.6 Publisher Expertise

## List Of Figures

### LIST OF FIGURES

Figure 1: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Region, 2019

Figure 2: Country wise Clinical Trials, 2019

Figure 3: Country wise Average Enrolment, 2019

Figure 4: Asia Pacific – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Figure 5: Europe – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Figure 6: Middle East Africa – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Figure 7: North America – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Figure 8: South and Central America – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Figure 9: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Phase

Figure 10: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Trial Status

Figure 11: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Type

Figure 12: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Sponsor Type

Figure 13: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials by Leading Sponsors

Figure 14: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Phase

Figure 15: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Trial Status

Figure 16: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Type

Figure 17: Focal Segmental Glomerulosclerosis (FSGS)- Average Enrolment by Type of Sponsors

Figure 18: Focal Segmental Glomerulosclerosis (FSGS)- Enrolment by Leading Sponsors

Figure 19: VPAResearch- Research Methodology

## List Of Tables

### LIST OF TABLES

Table 1: Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Snapshot- 2019

Table 2: Trials by Region, 2019

Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019

Table 4: Asia Pacific – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Table 5: Europe – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Table 6: Middle East Africa – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Table 7: North America – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Table 8: South and Central America – Country wise Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials and Enrolment

Table 9: Clinical Trials by Phase

Table 10: Clinical Trials by Trial Status

Table 11: Clinical Trials by Type

Table 12: Clinical Trials by Sponsor Type

Table 13: Clinical Trials by Leading Sponsors

Table 14: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Phase

Table 15: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Trial Status

Table 16: Focal Segmental Glomerulosclerosis (FSGS) Average Enrollment by Type

Table 17: Focal Segmental Glomerulosclerosis (FSGS)- Average Enrolment by Type of Sponsors

Table 18: Focal Segmental Glomerulosclerosis (FSGS)- Enrolment by Leading Sponsors

## I would like to order

Product name: 2019 Focal Segmental Glomerulosclerosis (FSGS) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

Product link: <https://marketpublishers.com/r/2BA637052F7EN.html>

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2BA637052F7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

